Yahoo Finance21h
MSD makes obesity play in up to $2bn deal for Hansoh’s GLP-1RA asset
Merck & Co (MSD) has entered an exclusive global licence agreement with China-based Hansoh Pharma for a preclinical oral ...
FDA says shortage of GLP-1 drug tirzepatide is over
The U.S. Food and Drug Administration reissued a decision first made by the agency in October that a shortage of the diabetes ...
Pharmabiz2h
Merck inks global license agreement with Hansoh Pharma for investigational oral GLP-1 receptor agonist
Merck, known as MSD outside of the United States and Canada, and Hansoh Pharma, a leading pharmaceutical company in Greater China, announced that they have entered into an exclusive global license ...
FierceBiotech1d
Merck & Co. boosts GLP-1 portfolio by paying $112M upfront for Hansoh's preclinical drug
Merck & Co. has added a second GLP-1 candidate to its pipeline, paying China’s Hansoh Pharma $112 million upfront for a ...
STAT1d
Pharmalittle: We’re reading about a Merck deal for an obesity pill, a departing FDA official, and more
Merck signed a deal worth up to $2 billion with Hansoh Pharma to develop and sell the Chinese biotech's oral obesity drug ...
What's Going On With Viking Therapeutics Stock On Wednesday?
Merck partners with Hansoh Pharma for GLP-1 drug development, while analysts highlight Viking's obesity assets as key for ...